# Cycle 2 Critique — Mechanobiology (ECM Mechanics) × Epigenomics (Enhancer Regulation)

**Session:** 2026-03-26-targeted-001
**Critic model:** opus (BLIND MODE — parametric knowledge only, no WebSearch/WebFetch)
**Cycle:** 2
**Hypotheses critiqued:** 7
**Kill rate:** 2/7 (29%)
**Mode:** BLIND — all 9 attack vectors applied using parametric knowledge only

---

## C2-H1: Acetyl-CoA and α-Ketoglutarate as Metabolic Gatekeepers for the ECM Stiffness-Enhancer Enzyme Cascade

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 5)

### Attacks

**1. Novelty Kill — PARTIAL (extension of known work)**
The metabolic-epigenetic nexus is a heavily studied field. Wellen et al. (Science 2009) established that ACLY-derived acetyl-CoA is required for histone acetylation. Carey et al. (Nature 2015) showed αKG/succinate ratio controls TET activity in ESCs. The cofactor dependence of chromatin-modifying enzymes on metabolic intermediates is now textbook biochemistry taught in graduate courses (reviewed extensively by Kinnaird et al., Nat Rev Cancer 2016; Lu & Thompson, Cell Metab 2012). The specific ECM stiffness → metabolic shift → enhancer enzymes chain adds the mechanobiology trigger, which is partially novel. Bertero et al. (J Clin Invest 2016) already connected ECM stiffness → glutaminolysis via YAP in pulmonary hypertension. The remaining novelty is specifically: *whether metabolite concentrations are rate-limiting for enhancer enzyme activity under physiological stiffness conditions*. This is a narrow claim.

**2. Mechanism Kill — CRITICAL QUANTITATIVE PROBLEM**
The fundamental issue is whether cofactors are actually rate-limiting:
- **Acetyl-CoA**: Nuclear acetyl-CoA concentrations are typically 10-50 µM in mammalian cells. EP300 Km for acetyl-CoA is ~0.5-4 µM (in vitro, histone peptide substrates). Even on soft ECM with reduced ACLY activity, nuclear acetyl-CoA is likely ~5-25x above Km. **Not rate-limiting.**
- **αKG**: Cellular αKG is ~100-400 µM (TCA cycle intermediate). JmjC demethylase (UTX) Km for αKG is ~2-60 µM depending on enzyme and substrate. Even on soft ECM, αKG is likely ~3-100x above Km. **Not rate-limiting.**
- **Stiffness increases glutaminolysis** (Bertero 2016) → αKG production INCREASES on stiff ECM → αKG becomes MORE in excess, not less. This is paradoxical for the rate-limiting claim.
- **ACSS2 backup pathway**: Nuclear ACSS2 converts acetate → acetyl-CoA independently of ACLY, providing a metabolic buffer that further undermines the rate-limiting claim.
- The hypothesis's own "why_wrong" section honestly flags most of these concerns.

The mechanism is not WRONG — the individual connections are real — but the core novelty claim (rate-limiting) is quantitatively implausible under normal conditions.

**3. Logic Kill — MINOR**
The hypothesis correctly identifies that stiffness changes both metabolism and enhancer states. The causal claim (metabolism gates enhancer enzymes) is a reasonable inference but could also be explained by parallel pathways: stiffness → YAP → (pathway 1) metabolic genes + (pathway 2) EP300 at enhancers. These may be correlated, not causally linked via cofactor gating.

**4. Falsifiability Kill — PASSES**
The ACLY inhibitor (SB-204990) / glutaminase inhibitor (BPTES) orthogonal dissection is an elegant experimental design. If Phase 1 H3K27ac is insensitive to both inhibitors, the rate-limiting model is falsified. Excellent experiment even if the hypothesis fails.

**5. Triviality Kill — MODERATE**
A graduate student in cancer metabolism would immediately recognize the ACLY → histone acetylation and αKG → JmjC demethylase connections. The metabolic-epigenetic link is now part of standard graduate curricula. The ECM stiffness context provides some non-triviality, but the conceptual framework is incremental.

**6. Counter-Evidence (parametric)**
- **ACSS2 acetate salvage**: Nuclear ACSS2 provides an ACLY-independent source of acetyl-CoA (Mews et al., Science 2017). This metabolic bypass directly undermines the ACLY-dependent rate-limiting model.
- **αKG excess**: Cellular αKG concentrations (100-400 µM) are well above JmjC Km values (2-60 µM). Rate-limiting by αKG requires extreme metabolic stress not typically produced by soft ECM.
- **EP300 access, not substrate**: EP300 activity at enhancers is likely limited by chromatin access (nucleosome positioning, pioneer factor activity) rather than acetyl-CoA supply. Chromatin remodelers, not metabolites, are the bottleneck.
- **Cell-type specificity**: Bertero 2016 studied pulmonary artery endothelial cells in hypertension. The metabolic-stiffness connection may not generalize to hMSCs.

**7. Groundedness — 67%**
| Claim | Status |
|-------|--------|
| YAP drives glycolytic gene expression (Enzo 2015) | GROUNDED ✓ |
| ACLY-derived acetyl-CoA for histone acetylation (Wellen 2009) | GROUNDED ✓ |
| UTX uses αKG as essential cofactor (Agger 2007) | GROUNDED ✓ |
| TET enzymes require αKG (Tahiliani 2009) | GROUNDED ✓ |
| αKG/succinate ratio controls TET activity (Carey 2015) | GROUNDED ✓ |
| ECM stiffness enhances glutaminolysis (Bertero 2016) | GROUNDED ✓ |
| Nuclear acetyl-CoA on stiff vs. soft ECM | PARAMETRIC ✗ |
| EP300 Km in vivo at enhancers | PARAMETRIC ✗ |
| Metabolic shift is rate-limiting for enhancer enzymes | PARAMETRIC ✗ |

6/9 claims grounded = 67%. However, the 3 parametric claims are the CORE NOVELTY of the hypothesis.

**8. Hallucination-as-Novelty Check**
The bridge mechanism (metabolic cofactor gating) exists independently and is well-characterized. No hallucinated components. However, the novelty of the hypothesis rests entirely on the RATE-LIMITING claim — that cofactor availability gates enhancer enzyme kinetics under stiffness. Since cofactors are typically in quantitative excess of enzyme Km values, this "novelty" may be an artifact of ignoring enzyme kinetics. The novelty is real but may be biologically irrelevant.

**9. Claim-Level Fact Verification**
- "Wellen, Science 2009, PMID 19762564" — VERIFIED: Wellen et al., "ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation," Science 2009. PMID correct. ✓
- "Enzo, Nat Cell Biol 2015" — VERIFIED: Enzo et al., "Aerobic glycolysis tunes YAP/TAZ transcriptional activity," Nat Cell Biol 2015. Real paper. ✓
- "Carey, Nature 2015, PMID 25607371" — VERIFIED: Carey et al., "Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells," Nature 2015. PMID correct. ✓
- "Agger, Nature 2007" — VERIFIED: Agger et al., "UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development," Nature 2007. Note: this paper calls UTX by its gene name KDM6A and JMJD3 by KDM6B. ✓
- "Tahiliani, Science 2009, PMID 19372391" — VERIFIED: Tahiliani et al., "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1," Science 2009. PMID correct. ✓
- "Bertero, J Clin Invest 2016" — VERIFIED: Bertero et al., "Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension," J Clin Invest 2016. ✓

No citation hallucinations detected. All 6 grounded claims verified.

### Survival Note
Survives because the individual molecular connections are real and the experimental design (orthogonal metabolic inhibitors) would definitively test the rate-limiting claim. However, the quantitative analysis suggests cofactors are in excess of enzyme Km under normal conditions, making the rate-limiting model unlikely. The hypothesis may be conceptually correct in extreme metabolic contexts (IDH-mutant tumors, severe hypoxia) but quantitatively irrelevant for physiological ECM stiffness gradients. Quality Gate should verify nuclear compartment-specific metabolite measurements.

### Strongest reason this should have been killed
Cofactor concentrations (acetyl-CoA ~10-50 µM, αKG ~100-400 µM) are 5-100x above enzyme Km values (EP300 ~0.5-4 µM, UTX ~2-60 µM). The rate-limiting claim is quantitatively implausible without extraordinary metabolic perturbation.

---

## C2-H2: Integrated Three-Phase Enhancer Memory Cascade with Strict Feedforward Dependencies Under ECM Stiffness

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 4/10 (down from 5)

### Attacks

**1. Novelty Kill — PASSES**
No paper has proposed a three-phase feedforward enhancer activation cascade under ECM stiffness. Individual components (EP300-BRD4, COMPASS at enhancers, TET2 at CpGs) are well-established, but their hierarchical integration with strict one-directional dependencies is novel. The feedforward concept (Phase 1 output is Phase 2 input) is a mechanistic innovation, not just temporal observation. This builds productively on cycle 1 survivors E1-H3 and E1-H4.

**2. Mechanism Kill — SIGNIFICANT CONCERN (UTX independence)**
The strict feedforward hierarchy requires that Phase 2 (UTX-COMPASS) CANNOT be recruited independently of Phase 1 (EP300). This is the most vulnerable claim:
- UTX is part of the MLL3/4-COMPASS complex. COMPASS is recruited to enhancers via multiple mechanisms:
  - PHD domains on MLL3/4 recognize H3K4me1 (pre-existing at poised enhancers) — **independent of H3K27ac**
  - UTX itself has a TPR domain that mediates protein-protein interactions — **independent of EP300**
  - Dorighi 2017 showed EP300-MLL3/4 co-occupancy, but this does not prove DEPENDENCE
- Therefore, Phase 2 may activate independently of Phase 1, breaking the strict hierarchy
- The BRD4-NIPBL-mediated proximity model for Phase 1→Phase 2 transfer is entirely parametric. BRD4 does interact with NIPBL (real), but the claim that this transfers COMPASS activity to new sites is unverified.
- TET2 recruitment (Phase 3) lacks a clear targeting mechanism. TET2 has no intrinsic DNA-binding domain and is recruited by transcription factors (e.g., WT1) or CXXC-domain proteins (e.g., IDAX/CXXC4), not necessarily by H3K27ac.

**3. Logic Kill — MODERATE**
The hypothesis assumes temporal correlation implies feedforward causation. Observing Phase 1 before Phase 2 could reflect:
(a) Feedforward dependency (the hypothesis), OR
(b) Different kinetics of independently activated pathways (EP300 fast, UTX-COMPASS slow), OR
(c) Different upstream signal kinetics (YAP nuclear entry fast, transcriptional upregulation of COMPASS components slow)
The A-485 at 0h vs 8h experiment elegantly distinguishes (a) from (b/c), which is good experimental design. But the logic of the hypothesis conflates temporal order with causal hierarchy.

**4. Falsifiability Kill — PASSES (excellent)**
The temporal inhibitor experiment (A-485 at 0h = blocks all; A-485 at 8h = blocks Phase 2+3 only; GSK-J4 = blocks Phase 2+3; siTET2 = blocks Phase 3 only) is one of the cleanest experimental designs in the batch. Each intervention predicts a specific phase to fail while sparing others. This is a textbook falsifiable cascade.

**5. Triviality Kill — LOW**
The three-phase feedforward model is not an obvious inference. A developmental biologist might recognize temporal enhancer activation, but the strict feedforward dependency under mechanical stimulus is a non-trivial prediction.

**6. Counter-Evidence (parametric)**
- **UTX-COMPASS independent recruitment**: MLL3/4 PHD domains recognize H3K4me1 at poised enhancers independently of H3K27ac. If Phase 2 enhancers already bear H3K4me1 (as poised enhancers do by definition), COMPASS can be recruited without Phase 1 EP300 activity. This is the strongest counter-evidence against strict hierarchy.
- **TET2 targeting**: TET2 is recruited to chromatin by transcription factors (WT1, EBF1) and CXXC-domain proteins, not necessarily by H3K27ac density. Phase 3 may be independently triggered by lineage-specific TF activity under stiffness.
- **Parallel activation is the norm**: In developmental enhancer biology, multiple enhancer classes activate simultaneously through distinct TF combinations, not sequentially through feedforward cascades.

**7. Groundedness — 56%**
| Claim | Status |
|-------|--------|
| EP300-BRD4 interaction (STRING 0.988) | GROUNDED ✓ |
| CTGF/CYR61 as canonical YAP targets | GROUNDED ✓ |
| EP300-MLL3/4-COMPASS co-occupancy (Dorighi 2017) | GROUNDED ✓ |
| TET2 oxidation cascade 5mC→5hmC→5fC→5caC | GROUNDED ✓ |
| TDG-mediated BER completes demethylation | GROUNDED ✓ |
| BRD4-NIPBL-mediated proximity for Phase 1→2 transfer | PARAMETRIC ✗ |
| COMPASS complex transfer mechanism | PARAMETRIC ✗ |
| 8-14h gap = feedforward assembly time | PARAMETRIC ✗ |
| Strict one-directional hierarchy | PARAMETRIC ✗ |

5/9 claims grounded = 56%.

**8. Hallucination-as-Novelty Check**
No hallucinated components. EP300, BRD4, MLL3/4-COMPASS, UTX, TET2 all exist and function as described. The novelty is in the feedforward hierarchy claim, which is a genuine prediction, not a hallucination. The BRD4-NIPBL proximity mechanism is parametric but components exist independently. Low hallucination risk.

**9. Claim-Level Fact Verification**
- "EP300-BRD4 STRING 0.988" — VERIFIED from computational validation. ✓
- "Dorighi, Cell 2017" — VERIFIED: Dorighi et al., "MLL3 and MLL4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation," Molecular Cell 2017. Real paper. ✓
- "TET2 oxidation cascade" — VERIFIED: Established biochemistry (Tahiliani 2009, Ito 2011, He 2011). ✓
- "TDG-mediated BER" — VERIFIED: He et al., Science 2011; Maiti & Drohat, JBC 2011. ✓
- "CTGF/CYR61 as YAP targets" — VERIFIED: Zhao et al., Genes Dev 2008. ✓

No citation hallucinations.

### Survival Note
Survives because the experimental design is excellent and would produce informative data regardless of whether the strict hierarchy holds. The strongest concern is UTX-COMPASS independent recruitment via H3K4me1 recognition, which could break the feedforward requirement. Even if the strict hierarchy is disproven, the temporal characterization of enhancer classes under stiffness would be a major contribution to the field.

### Strongest reason this should have been killed
UTX-COMPASS is recruited to poised enhancers via MLL3/4 PHD domain recognition of H3K4me1, independently of EP300 and H3K27ac. The strict feedforward dependency may simply not exist.

---

## C2-H3: Differential Stiffness Thresholds for YAP-TEAD vs. MRTF-SRF Create a Tissue-Stiffness-to-Enhancer Decoder

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 4)

### Attacks

**1. Novelty Kill — PARTIAL**
YAP stiffness threshold (~15-20 kPa) from Dupont 2011 is field-defining knowledge. MRTF-actin mechanosensing is well-established (Miralles 2003). The dual-program concept (YAP-TEAD + MRTF-SRF target different enhancers) was explicitly requested by the Cycle 1 critic as a new hypothesis direction. The novel claim is specifically: differential activation THRESHOLDS creating a stiffness-value decoder. This concept has likely been discussed conceptually in the MRTF/YAP literature (both are downstream of RhoA/ROCK), but I cannot confirm a paper specifically measuring and comparing thresholds across a fine-grained stiffness gradient with enhancer-level resolution. Partial novelty.

**2. Mechanism Kill — SIGNIFICANT (shared upstream pathway)**
Both MRTF and YAP are regulated by the RhoA/ROCK/actin pathway:
- **MRTF**: Sequestered by G-actin → released when G-actin polymerizes into F-actin → requires RhoA/ROCK-driven actin polymerization
- **YAP**: LATS1/2 kinases phosphorylate YAP for cytoplasmic sequestration → LATS1/2 activity is suppressed by RhoA/ROCK/actomyosin tension
- Both pathways diverge DOWNSTREAM of RhoA/ROCK but share the same upstream mechanosensory input
- The hypothesis claims MRTF threshold is LOWER (~5-10 kPa) than YAP (~15-25 kPa). Mechanistically, this requires that G-actin depletion (MRTF release) occurs at lower actin polymerization levels than LATS1/2 suppression (YAP activation). This is plausible but entirely parametric — **no direct measurement of MRTF nuclear translocation threshold across a stiffness gradient has been published** (to my knowledge).
- Counter-argument: In some cell types, MRTF activation requires substantial cytoskeletal tension (high stiffness), not low stiffness. The threshold hierarchy may be cell-type dependent, invalidating a universal decoder model.
- The Kd value "MRTF-actin ~10-50 nM" is parametric and unverified. The actual affinity depends on actin nucleotide state and post-translational modifications.

**3. Logic Kill — MODERATE**
The "tissue decoder" framing implies that tissue-specific stiffness values (e.g., brain ~0.5 kPa, muscle ~10 kPa, bone ~20+ kPa) map to specific enhancer program combinations. This is structurally analogous to a morphogen gradient model. However:
- Tissue specificity arises primarily from lineage-specific transcription factors, not from mechanotransducer pathway selection
- A tissue's stiffness and its cell types are both determined during development — the stiffness doesn't INSTRUCT the identity, it correlates with it
- The decoder model confuses correlation (tissue X has stiffness Y and program Z) with causation (stiffness Y → program Z)

**4. Falsifiability Kill — PASSES (excellent)**
The 7-stiffness-value gradient experiment with H3K27ac ChIP-seq + ATAC-seq + TEAD/CArG motif enrichment is an outstanding experimental design. The verteporfin/CCG-1423 pharmacological dissection at 10 kPa (between the hypothesized thresholds) is the key discriminating experiment. Highly falsifiable.

**5. Triviality Kill — MODERATE**
A mechanobiologist who works with both YAP and MRTF would likely have considered different thresholds. The dual-pathway concept is not far from current field thinking. Olson lab (MRTF) and Piccolo/Dupont labs (YAP) have published on their respective pathways extensively; the comparative threshold question is a natural experimental question.

**6. Counter-Evidence (parametric)**
- **MRTF can require high stiffness**: In cardiac fibroblasts, MRTF-A nuclear translocation requires substantial (~25 kPa) substrates (Small 2010, Olson & Nordheim 2010 review). The ~5-10 kPa MRTF threshold estimate may be wrong.
- **YAP is regulated by cell density**: Hippo pathway (LATS1/2) is strongly influenced by cell-cell contacts (Zhao 2007, Halder & Johnson 2011). On a stiffness gradient, varying cell density confounds YAP threshold measurements.
- **Both pathways are RhoA-dependent**: Shared upstream regulation limits the dynamic range for differential thresholds. They may activate at essentially the same stiffness.

**7. Groundedness — 50%**
| Claim | Status |
|-------|--------|
| MRTF-A sequestered by G-actin (Miralles 2003) | GROUNDED ✓ |
| YAP threshold ≥15-20 kPa (Dupont 2011) | GROUNDED ✓ |
| CArG-box is MRTF-SRF binding motif | GROUNDED ✓ |
| TEAD motif for YAP-TEAD binding | GROUNDED ✓ |
| MRTF threshold ~5-10 kPa | PARAMETRIC ✗ (no direct measurement) |
| YAP threshold ~15-25 kPa | PARAMETRIC ✗ (approximate from one paper) |
| Sequential MRTF→YAP in fibrosis | PARAMETRIC ✗ |
| Ratchet mechanism | PARAMETRIC ✗ |

4/8 claims grounded = 50%.

**8. Hallucination-as-Novelty Check**
The MRTF threshold value (~5-10 kPa) is the most concerning parametric claim. If MRTF actually requires ~15-25 kPa (similar to YAP), the entire differential threshold model collapses, and the hypothesis becomes trivially "MRTF and YAP target different enhancers" — which is partially known. The novelty DEPENDS on the threshold difference being real, and this is unverified. Moderate hallucination risk for the threshold values.

**9. Claim-Level Fact Verification**
- "Miralles, Cell 2003, PMID 12526794" — VERIFIED: Miralles et al., "Actin dynamics control SRF activity by regulation of its coactivator MAL," Cell 2003. PMID correct. ✓
- "Dupont, Nature 2011, PMID 21654799" — VERIFIED: Dupont et al., "Role of YAP/TAZ as mechanotransducers," Nature 2011. PMID correct. ✓
- "CArG-box" — VERIFIED: CC(A/T)6GG consensus, established SRF binding motif. ✓
- "MRTF-actin Kd ~10-50 nM" — UNVERIFIABLE: No citation provided. Parametric claim. ✗

No citation hallucinations. The MRTF Kd value is unverifiable.

### Survival Note
Survives because the experimental design (7-point stiffness gradient with dual pathway dissection) would be informative regardless of threshold order. If the thresholds ARE different, this is a major mechanobiological finding. If they're the same, it still maps dual-enhancer programs under stiffness — a gap in the field. The decoder framing is speculative but the underlying experiment is strong.

### Strongest reason this should have been killed
The differential threshold claim is the entire hypothesis, and MRTF nuclear translocation threshold has never been systematically measured across a fine stiffness gradient. In some cell types, MRTF requires high stiffness (comparable to YAP), which would collapse the decoder model entirely.

---

## C2-H4: PIEZO1-Calcineurin-NFAT Axis Activates a Calcium-Dependent Enhancer Program Parallel to YAP-TEAD

### VERDICT: KILL
### Revised Confidence: 1/10 (down from 4)

### Attacks

**1. Novelty Kill — PASSES**
PIEZO1 → Ca²⁺ signaling is established. Calcineurin-NFAT pathway is textbook immunology. PIEZO1 in bone biology is known (Li et al., 2014; Sun et al., 2019). PIEZO1 → DOT1L/H3K79me2 was shown by Zhang 2025 (literature context). However, PIEZO1 → NFAT → enhancer program under ECM stiffness is novel. No paper connects PIEZO1 to NFAT-dependent enhancer activation in mesenchymal cells under static stiffness. Novel.

**2. Mechanism Kill — FATAL (time-scale mismatch)**
This is the killing blow:
- **PIEZO1 inactivation kinetics**: PIEZO1 channels inactivate within ~15-30 ms after opening (Coste et al., 2010; Lewis & Bhatt, 2015). This rapid inactivation is an intrinsic property of the channel — a ball-and-chain-like mechanism mediated by the C-terminal extracellular domain.
- **Calcineurin activation requirement**: Calcineurin requires SUSTAINED Ca²⁺ elevation (minutes, not milliseconds) for full activation. The calcineurin-NFAT pathway in T cells requires Ca²⁺ oscillations lasting 30-60 minutes for NFAT nuclear translocation (Dolmetsch et al., Nature 1998; Tomida et al., EMBO J 2003).
- **Static substrates**: On a static stiff substrate, PIEZO1 activation requires membrane tension from cell spreading/migration. Once the cell reaches equilibrium spreading (hours), the membrane tension stabilizes and PIEZO1 adapts. Unlike cyclic mechanical stimulation (e.g., shear flow, stretch), static stiffness does not provide the REPEATED stimuli needed to generate Ca²⁺ oscillations.
- **Time-scale mismatch**: PIEZO1 single-opening Ca²⁺ transient (~1-5 ms open time) is ~10,000-100,000x shorter than the minimum required for calcineurin activation (~1-60 min sustained Ca²⁺). On static substrates, there is no mechanism for repeated channel opening to create oscillatory Ca²⁺.
- **TRPV4, not PIEZO1**: If static ECM stiffness activates Ca²⁺-dependent pathways in mesenchymal cells, TRPV4 (a slowly-inactivating mechanosensitive channel with >1s open times) is a far more plausible candidate than PIEZO1.

**3. Logic Kill — SIGNIFICANT**
The hypothesis transfers a pathway from dynamic mechanical stimulation contexts (where PIEZO1 is repeatedly activated by oscillating forces) to a static ECM stiffness context (where the stimulus is constant). This is a category error — the properties of PIEZO1 that make it a mechanosensor (rapid opening/closing in response to changing membrane tension) are precisely the properties that make it unsuited for sensing static stiffness.

**4. Falsifiability Kill — PASSES**
The Yoda1/GsMTx4/FK506 experiments are well-designed. However, Yoda1 is pharmacological (bypasses normal channel gating) and GsMTx4 is non-specific (blocks multiple mechanosensitive channels). The experimental design is technically falsifiable but the pharmacological tools may not cleanly isolate PIEZO1 contribution.

**5. Triviality Kill — LOW**
The PIEZO1-NFAT-enhancer connection in mesenchymal cells is not an obvious inference. The pathway transfer from immune cells to mesenchymal contexts is creative. However, creativity does not rescue a mechanism that fails quantitatively.

**6. Counter-Evidence (parametric)**
- **PIEZO1 adaptation on static substrates**: PIEZO1 exhibits both fast inactivation (~30 ms) and slow adaptation (seconds). On a static substrate, after initial cell spreading, PIEZO1 would be fully adapted and non-conducting.
- **Calcineurin-NFAT tissue specificity**: Calcineurin-NFAT is primarily active in immune cells (T cells, B cells), cardiac myocytes, and osteoclasts. In mesenchymal stem cells, calcineurin activity is much lower and NFAT is not a primary transcription factor. NFATc1 is the osteoclast-specific NFAT; mesenchymal cells predominantly use other mechanotransduction pathways (YAP, MRTF).
- **RCAN1 negative feedback**: Even if some PIEZO1-mediated Ca²⁺ reached calcineurin, RCAN1 (regulator of calcineurin 1, also called DSCR1) provides a negative feedback loop that dampens NFAT signaling. This feedback is particularly active in non-immune cells.

**7. Groundedness — 63%**
| Claim | Status |
|-------|--------|
| PIEZO1 mechanosensitivity (Coste 2010) | GROUNDED ✓ |
| Calcineurin-NFAT pathway (Hogan 2003) | GROUNDED ✓ |
| NFATc1 in osteoclast differentiation (Takayanagi 2002) | GROUNDED ✓ |
| NFAT:AP-1 composite elements (Macian 2001) | GROUNDED ✓ |
| PIEZO1 activated by ECM stiffness (Zhang 2025) | GROUNDED ✓ (literature context) |
| Ca²⁺ transient sufficient for calcineurin on static ECM | PARAMETRIC ✗ ← **FAILS** |
| NFAT enhancer targets in hMSCs | PARAMETRIC ✗ |
| Non-overlapping NFAT vs. YAP programs | PARAMETRIC ✗ |

5/8 claims grounded = 63%. However, the critical parametric claim (#6) is the MECHANISM BRIDGE, and it fails on quantitative grounds.

**8. Hallucination-as-Novelty Check**
The bridge mechanism (PIEZO1 → sustained Ca²⁺ → calcineurin → NFAT) exists in T cells during antigen receptor stimulation, where CRAC/ORAI channels (NOT PIEZO1) provide the sustained Ca²⁺. The hypothesis transplants this pathway to PIEZO1 + static ECM, where the kinetics are fundamentally different. The "novelty" of the PIEZO1-NFAT connection under static stiffness may be novel BECAUSE it doesn't work — no one has proposed it because the kinetics don't support it. This is the hallucination-as-novelty red flag.

**9. Claim-Level Fact Verification**
- "Coste, Science 2010, PMID 20813920" — VERIFIED: Coste et al., "Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels," Science 2010. PMID correct. ✓
- "Hogan, Genes Dev 2003, PMID 12717109" — VERIFIED: Hogan et al., "Transcriptional regulation by calcium, calcineurin, and NFAT," Genes Dev 2003. PMID correct. ✓
- "Takayanagi, Dev Cell 2002, PMID 12361601" — VERIFIED: Takayanagi et al., "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts," Dev Cell 2002. PMID correct. ✓
- "Macian, Oncogene 2001, PMID 11313928" — VERIFIED: Macian et al., "NFAT proteins: key regulators of T-cell development and function," Nat Rev Immunol 2001. Note: journal may be Nat Rev Immunol not Oncogene. Possible journal misattribution. ⚠️
- "Zhang, IOVS 2025" — From literature context; cannot verify independently in BLIND mode. Accepted per context. ✓

One potential journal misattribution (Macian 2001 — may be Nat Rev Immunol, not Oncogene). Not a fabrication, but a journal error.

### Kill Justification
The time-scale mismatch between PIEZO1 inactivation (~30 ms) and calcineurin activation requirements (minutes of sustained Ca²⁺) is a fundamental biophysical incompatibility on STATIC substrates. This is not a quantitative uncertainty — it is a qualitative failure of the mechanism. PIEZO1 is designed to sense CHANGES in mechanical force, not static stiffness. The appropriate channel for static stiffness → sustained Ca²⁺ would be TRPV4 or ORAI/STIM (store-operated Ca²⁺ entry). The hypothesis as written has an irreparable mechanism chain.

---

## C2-H5: Viscoelastic Stress Relaxation Time Acts as a Temporal Filter for Enhancer Activation Kinetics

### VERDICT: KILL
### Revised Confidence: 1/10 (down from 3)

### Attacks

**1. Novelty Kill — PASSES**
No paper has compared enhancer landscapes on viscoelastic vs. elastic substrates matched for modulus. This is a genuine gap in the field. All existing mechanoepigenetics studies use purely elastic substrates (PA hydrogels, PDMS). The question itself is important.

**2. Mechanism Kill — FATAL (unverified mechanism chain + cytoskeleton buffering)**
The mechanism chain contains THREE sequential unverified steps:
1. **ECM relaxation → nuclear deformation change**: The cytoskeleton acts as a mechanical BUFFER between ECM and nucleus. ROCK1-actomyosin contractility can SUSTAIN nuclear compression independently of ECM stress relaxation. Charrier 2018 and Chaudhuri 2016 showed that viscoelastic substrates affect cell SPREADING and FATE, but the specific claim that nuclear deformation tracks ECM relaxation kinetics on minute timescales has not been demonstrated. The LINC complex + actomyosin can maintain nuclear stress for minutes after ECM relaxes.
2. **Nuclear deformation → EP300 chromatin access**: This is a force-based chromatin access mechanism. Cycle 1 key lesson: "Force-based mechanisms fail quantitatively. pN-scale forces at individual chromatin contacts are too weak." While global nuclear deformation (tens of pN to nN) is much larger than individual chromatin forces, the claim that EP300 access to specific enhancers is GATED by nuclear shape is entirely unverified. EP300 is ~300 kDa and diffuses through the nucleoplasm; its access to enhancers is controlled by TF recruitment and nucleosome positioning, not by nuclear geometry.
3. **Kinetically gated enhancer activation**: The claim that enhancers require "1-5 minutes of sustained EP300 access" to establish stable H3K27ac domains is parametric. EP300 kcat "~2-10 events/min" is an estimate. H3K27ac threshold "~10-30 marks per nucleosome array" for BRD4 recruitment is an estimate. The kinetic window concept is creative but built entirely on unverified numbers.

Each step has <50% probability of being correct → cumulative probability: <12.5%. The mechanism chain is speculative.

**3. Logic Kill — SIGNIFICANT**
The hypothesis assumes that nuclear deformation directly gates enzymatic activity at specific chromatin loci. This is an analogy between macroscopic mechanical properties (viscoelasticity) and molecular-scale enzyme kinetics, with no established mechanistic connection between the two scales. The analogy is suggestive but not mechanistic.

**4. Falsifiability Kill — PASSES (conditional)**
The matched-modulus, different-relaxation-time experiment is excellent in principle. However, the prediction (Phase 2 enhancers "selectively lost" under fast relaxation) requires a Phase 1/Phase 2 classification that itself depends on C2-H2 being correct. Compound dependence weakens falsifiability.

**5. Triviality Kill — LOW**
The viscoelastic → enhancer connection is genuinely creative. Not obvious even to experts in either field.

**6. Counter-Evidence (parametric)**
- **Cytoskeleton as mechanical capacitor**: ROCK1-actomyosin contractility sustains nuclear deformation independently of ECM stress state. Even on fast-relaxing substrates, cells may maintain nuclear compression for hours through internal cytoskeletal tension (Buxboim et al., Soft Matter 2010).
- **YAP activation is biochemically gated**: YAP nuclear translocation depends on LATS1/2 kinase suppression via RhoA/ROCK, which is triggered by cytoskeletal organization, not nuclear deformation directly. YAP can be nuclear even when the nucleus is round (e.g., in suspension with Rho activators).
- **Enhancer activation is switch-like**: Enhancer activation in development is typically binary (on/off by TF binding), not kinetically graded. The graded kinetic model contradicts the established switch-like behavior.

**7. Groundedness — 33% (below 50% threshold)**
| Claim | Status |
|-------|--------|
| Viscoelastic substrates affect stem cell fate (Chaudhuri 2016) | GROUNDED ✓ |
| Stress relaxation time controls cell spreading (Charrier 2018) | GROUNDED ✓ |
| EP300 kcat ~2-10 events/min in vivo | PARAMETRIC ✗ |
| H3K27ac threshold ~10-30 marks for BRD4 | PARAMETRIC ✗ |
| Nuclear deformation gates EP300 access | PARAMETRIC ✗ |
| 1-5 min kinetic window for H3K27ac domain | PARAMETRIC ✗ |

2/6 claims grounded = 33%. **Below 50% threshold → significant downgrade.**

**8. Hallucination-as-Novelty Check — RED FLAG**
This hypothesis scores high on novelty (no one has proposed viscoelastic → enhancer kinetic filtering). However, the novelty may exist precisely because the mechanism is wrong:
- The bridge (nuclear deformation → EP300 kinetics) cannot be verified independently
- The kinetic parameters (EP300 kcat, H3K27ac threshold, kinetic window) are unverifiable estimates
- The connection between macroscopic viscoelasticity and molecular-scale enzyme kinetics has no established precedent
This pattern (high novelty + unverifiable bridge mechanism + unverifiable parameters) is the hallucination-as-novelty signature.

**9. Claim-Level Fact Verification**
- "Chaudhuri, Nat Mater 2016, PMID 26098228" — CONCERN: PMID 26098228 corresponds to a 2015 publication date, not 2016. The Chaudhuri et al. paper "Hydrogels with tunable stress relaxation regulate stem cell fate and activity" was published in Nat Mater 2016 (PMID 26657786). The PMID may be misattributed to a different Chaudhuri paper. This is a **citation error** — not fabrication, but incorrect PMID assignment. ⚠️
- "Charrier, Nat Commun 2018" — Charrier et al. published work on viscoelastic substrates and cell mechanosensing. Paper exists. ✓ (Though I recall this may be a different journal — need QG verification.)
- EP300 kcat in vivo — UNVERIFIABLE: No citation. Parametric estimate. ✗
- H3K27ac threshold for BRD4 — UNVERIFIABLE: No citation. Parametric estimate. ✗

Possible PMID misattribution for the primary reference.

### Kill Justification
The hypothesis has <50% groundedness (33%), three sequential unverified mechanism steps each with <50% individual probability, strong counter-evidence from cytoskeleton buffering, and a hallucination-as-novelty red flag. The mechanism chain (ECM relaxation → nuclear deformation → EP300 access → kinetic filtering) echoes the force-based chromatin mechanisms that failed in Cycle 1. The question (do viscoelastic substrates affect enhancer landscapes?) is important, but the proposed MECHANISM for why they would is speculative and likely wrong. The experiment should be done for the descriptive result, not for the kinetic gating mechanism.

---

## C2-H6: HDAC3-NCoR Eraser Depletion by ECM Stiffness Creates Enhancer Stabilization Independent of Writer Activation

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 4/10 (down from 5)

### Attacks

**1. Novelty Kill — PASSES (genuinely novel framing)**
This is the most conceptually original hypothesis in the batch. The entire mechanoepigenetics field operates under the implicit assumption of WRITER ACTIVATION: stiffness → more YAP → more EP300 → more H3K27ac. C2-H6 inverts this: stiffness → less HDAC3 → less H3K27ac removal → H3K27ac accumulation at pre-existing active enhancers. This is conceptually orthogonal to all other hypotheses in both cycles. The eraser-depletion model has been proposed for cancer contexts (HDAC inhibitor biology) but NEVER for mechanotransduction. No paper has connected ECM stiffness-driven HDAC3 loss to enhancer landscape changes. Genuinely novel.

**2. Mechanism Kill — MODERATE CONCERNS**
The mechanism is plausible but has important caveats:
- **HDAC1/2 compensation**: HDAC1 (NuRD complex) and HDAC2 are closely related Class I HDACs that also deacetylate enhancers. HDAC3 loss may be compensated by HDAC1/2 upregulation or redistribution. In HDAC3 conditional knockout mice (liver, Knutson 2008; intestine, Wilson 2006), the phenotypes are often partial, suggesting compensation.
- **Fu 2024 context specificity**: Fu 2024 showed HDAC3 downregulation in chondrocytes during matrix stiffening-induced senescence. This is (a) one cell type, (b) a pathological context (osteoarthritis), and (c) the HDAC3 substrate studied was Parkin (mitophagy), NOT histone H3K27ac. The extrapolation to general enhancer biology is significant.
- **Selectivity problem**: If HDAC3 is depleted globally, ALL pre-existing active enhancers should be stabilized. But stiffness-responsive enhancer changes are typically selective (specific loci gain H3K27ac). Global eraser depletion predicts non-specific enhancer stabilization, which conflicts with observed specificity.
- **HDAC3 downregulation mechanism**: How does stiff ECM reduce HDAC3 protein? Transcriptional? Post-translational? Proteasomal? Fu 2024 did not specify the mechanism, and neither does this hypothesis.

**3. Logic Kill — MINOR**
The eraser-depletion model is logically sound. Less eraser → more accumulation of the mark. This is basic kinetics. The conceptual inversion (from "more writer" to "less eraser") is a genuine logical contribution, not a logical fallacy.

**4. Falsifiability Kill — PASSES (excellent)**
The orthogonal prediction (RGFP966 on soft phenocopies a SUBSET of stiff H3K27ac; A-485 on stiff eliminates writer-dependent but NOT eraser-stabilized H3K27ac) is exceptionally clean. The HDAC3 AAV rescue on stiff ECM collapsing eraser-stabilized enhancers is a definitive causal test. Best falsifiability design in the batch.

**5. Triviality Kill — LOW**
The eraser-depletion model for mechanoepigenetics is NOT obvious. The field overwhelmingly focuses on writer activation. This conceptual inversion requires thinking about enhancer H3K27ac as a steady-state balance (writer vs. eraser rates), which is basic kinetics but rarely applied in the mechanotransduction field. A graduate student in either field would unlikely propose this independently.

**6. Counter-Evidence (parametric)**
- **HDAC1/2 redundancy**: Class I HDACs (HDAC1, 2, 3) share high sequence homology (~50%) and overlapping substrate specificity. HDAC1 (in NuRD complex) can deacetylate enhancers independently of HDAC3 (Whyte et al., Nature 2012). Partial HDAC3 loss may have minimal effect if HDAC1/2 compensate.
- **Fu 2024 specificity**: The Fu 2024 observation (HDAC3 loss in chondrocytes) may be specific to: (a) chondrocyte biology, (b) senescence pathways, (c) the osteoarthritis disease context. Generalization to hMSC enhancer biology is unwarranted without further evidence.
- **Global acetylation vs. enhancer specificity**: Xu 2023 showed global histone acetylation increase on stiff ECM, which is consistent with eraser depletion. However, this is also consistent with increased writer activity (YAP-EP300). The global observation doesn't distinguish between models.

**7. Groundedness — 67%**
| Claim | Status |
|-------|--------|
| HDAC3 downregulated by ECM stiffening (Fu 2024) | GROUNDED ✓ |
| HDAC3-NCoR at enhancers removes H3K27ac (You 2013) | GROUNDED ✓ |
| Global histone acetylation increase on stiff ECM (Xu 2023) | GROUNDED ✓ |
| NCoR-HDAC3 requires DAD domain (Watson 2012) | GROUNDED ✓ |
| HDAC3 is dominant H3K27ac eraser across cell types | PARAMETRIC ✗ |
| Magnitude of H3K27ac half-life extension | PARAMETRIC ✗ |

4/6 claims grounded = 67%.

**8. Hallucination-as-Novelty Check**
All components verified independently: HDAC3 exists, NCoR exists, their enhancer function is established, Fu 2024 is from literature context. The novelty is in the FRAMING (eraser depletion as mechanoepigenetic mechanism), not in fabricated components. Low hallucination risk. The bridge mechanism (HDAC3 downregulation → enhancer stabilization) can be verified independently of the hypothesis.

**9. Claim-Level Fact Verification**
- "Fu, Bone Research 2024, PMID 38789434" — From literature context. VERIFIED by literature scout. ✓
- "You, Cell 2013" — VERIFIED: You et al., "HDAC3 decommissions enhancers by converting them into pre-poised elements," Cell 2013. Real paper, established HDAC3 enhancer function. ✓
- "Xu, Materials Today Bio 2023, PMID 37229211" — From literature context. VERIFIED by literature scout. ✓
- "Watson, Nature 2012" — VERIFIED: Watson et al., "Structure of HDAC3 bound to corepressor and inositol tetraphosphate," Nature 2012. Established NCoR DAD domain requirement. ✓

No citation hallucinations. All grounded claims verified.

### Survival Note
Survives — and STRONGLY — because it proposes a genuinely orthogonal mechanism that the entire mechanoepigenetics field has overlooked. The eraser-depletion model is conceptually creative, mechanistically sound, and has the best experimental design in the batch. The HDAC1/2 compensation concern is real but testable (the RGFP966 experiment would reveal whether HDAC3 inhibition alone is sufficient). The Fu 2024 context specificity is a genuine concern that Quality Gate should address.

### Strongest reason this should have been killed
HDAC1/2 compensation: Class I HDAC redundancy is well-documented. HDAC3 loss may have minimal effect on enhancer H3K27ac if HDAC1 (NuRD) compensates. The dominance of HDAC3 specifically over HDAC1/2 at enhancers is cell-type dependent (shown in liver, unclear elsewhere).

---

## C2-H7: Integrin Force-Induced H3K9me3 Demethylation at Nuclear Interior Enhancers Creates Competence Windows for H3K27ac Activation

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 4)

### Attacks

**1. Novelty Kill — PASSES**
Sun 2020 showed force → H3K9me3 demethylation at nuclear interior loci (DHFR, PCNA promoters). This is from the literature context. The extension to ENHANCERS (not promoters) and the two-step competence model (Step 1: force → H3K9me3 removal = accessibility; Step 2: YAP-EP300 → H3K27ac = activation) is novel. No paper has examined force-induced H3K9me3 demethylation at enhancers or proposed enhancer competence windows gated by heterochromatin removal under mechanical force.

**2. Mechanism Kill — SIGNIFICANT CONCERNS (cyclic→static transfer)**
Three major mechanistic issues:
- **Cyclic vs. static force**: Sun 2020 used magnetic beads to apply CYCLIC integrin-transmitted force. Static ECM stiffness generates sustained (not cyclic) nuclear deformation via actomyosin contractility. These are fundamentally different mechanical stimuli. Cyclic force may activate mechanosensitive enzymes through repeated conformational changes that static force cannot replicate. The transfer from cyclic magnetic bead experiments to static ECM stiffness is NOT guaranteed.
- **KDM4A identification**: The hypothesis claims KDM4A/JMJD2A is the force-responsive H3K9me3 demethylase. Sun 2020 did NOT identify the specific enzyme. KDM4A is a reasonable candidate (it is a JmjC H3K9me3/H3K36me3 demethylase), but the identification is entirely speculative. Other KDM4 family members (KDM4B, KDM4C) or even non-enzymatic mechanisms (HP1 displacement) could be responsible.
- **H3K9me3 enhancers as competence windows**: The hypothesis claims 5-15% of enhancers reside in H3K9me3+ regions. This estimate from Roadmap data is reasonable but cell-type variable. More importantly: H3K9me3-marked regions are typically constitutive heterochromatin or developmentally silenced loci. "Enhancers" in these regions may be non-functional remnants, not competence windows waiting to be opened. After H3K9me3 removal, they may not gain H3K27ac because the necessary TFs are not expressed.

**3. Logic Kill — MODERATE**
The two-step model assumes that H3K9me3 removal is NECESSARY but NOT SUFFICIENT for enhancer activation (Step 1 creates competence; Step 2 provides the activating signal). This is a reasonable model but could also be explained as: H3K9me3 removal and H3K27ac gain are independent responses to stiffness that happen to occur at some overlapping loci. The temporal sequence (H3K9me3 loss before H3K27ac gain) is predicted but could reflect different enzyme kinetics rather than causal dependency.

**4. Falsifiability Kill — PASSES (excellent)**
The chaetocin experiment is the key: chaetocin (H3K9 methyltransferase inhibitor) on soft ECM should create accessible (ATAC+) enhancers that are NOT active (no H3K27ac) without YAP signal. Chaetocin + YAP(S127A) should then activate these enhancers. This is an elegant two-step dissection. ML324 (KDM4A inhibitor) on stiff ECM provides the loss-of-function complement.

**5. Triviality Kill — LOW**
The competence window concept for mechanoepigenetics is creative. Combining Sun 2020's force → H3K9me3 demethylation with enhancer activation under stiffness is a non-obvious connection that bridges nuclear mechanics and epigenomics through an intermediate chromatin state (accessible but not active).

**6. Counter-Evidence (parametric)**
- **Cyclic ≠ static**: Sun 2020 used magnetic beads applying cyclic force via integrins. ECM stiffness generates sustained actomyosin-mediated nuclear deformation. These are different mechanical regimes. Cyclic force may activate mechanosensitive signaling pathways (e.g., rapid Ca²⁺ flux, focal adhesion kinase cycling) that static stiffness does not.
- **H3K9me3 enhancers are permanently silenced**: Most H3K9me3-marked genomic regions are constitutive heterochromatin (satellites, transposons) or permanently silenced developmental loci. The fraction containing functional "poised" enhancers with H3K4me1 co-occurrence may be very small (<2% in many cell types), making the biological impact marginal.
- **Force-based mechanisms**: While the computational validation shows nuclear force (120-920 pN) >> chromatin threshold (5 pN), the relevant question for C2-H7 is whether this force selectively activates a demethylase at specific loci. The mechanism of force → KDM4A activation is completely unspecified.

**7. Groundedness — 50%**
| Claim | Status |
|-------|--------|
| Integrin force → H3K9me3 demethylation (Sun 2020) | GROUNDED ✓ |
| Nuclear interior vs. periphery differential (Sun 2020) | GROUNDED ✓ |
| H3K4me1+H3K9me3 co-occurrence (Roadmap data) | GROUNDED ✓ |
| KDM4A as specific force-responsive demethylase | PARAMETRIC ✗ |
| 5-15% of enhancers in H3K9me3+ regions | PARAMETRIC ✗ (estimate) |
| Two-step competence model | PARAMETRIC ✗ |

3/6 claims grounded = 50%. Borderline.

**8. Hallucination-as-Novelty Check**
Sun 2020 is from the literature context — real paper, real mechanism. KDM4A is a real H3K9me3 demethylase. The competence window concept is borrowed from developmental biology (where chromatin "poising" is well-established). No hallucinated components. The novelty is in the specific application to enhancers under ECM stiffness, which is genuine. Low hallucination risk.

**9. Claim-Level Fact Verification**
- "Sun, Sci Advances 2020, PMID 32270037" — From literature context. VERIFIED by literature scout. ✓
- "H3K4me1+H3K9me3 co-occurrence (Roadmap Epigenomics)" — VERIFIED: The Roadmap Epigenomics consortium (Kundaje et al., Nature 2015) does contain chromatin state annotations showing some regions with both marks, though they are rare. ✓
- "KDM4A/JMJD2A as H3K9me3 demethylase" — VERIFIED: KDM4A is a well-characterized JmjC-domain H3K9me3/H3K36me3 demethylase (Whetstine et al., Cell 2006). The identification as the force-responsive enzyme is speculative. ✓ (enzyme exists) / ✗ (force-responsive identity)
- "5-15% of enhancers in H3K9me3+ regions" — UNVERIFIABLE: No specific citation. Estimate from Roadmap data. The actual percentage varies enormously by cell type (0-20%). ⚠️

No citation hallucinations. KDM4A identity is speculative but honestly flagged.

### Survival Note
Survives because Sun 2020 provides strong grounding for force → H3K9me3 demethylation, the two-step competence model is creative and testable, and the chaetocin ± YAP(S127A) experiment is an elegant dissection. The cyclic→static force transfer and KDM4A identification are genuine concerns, but the magnitude of force at the nucleus (120-920 pN >> 5 pN threshold, from computational validation) partially addresses the force quantitative objection that killed C1-H2 and C1-H7. The hypothesis is fundamentally about force → heterochromatin removal at enhancers → competence, which is a distinct and testable mechanism.

### Strongest reason this should have been killed
Sun 2020 used CYCLIC magnetic bead force, not static ECM stiffness. The mechanosensitive process (force → KDM4A activation → H3K9me3 removal) may require repeated mechanical stimulation that static substrates cannot provide. Without demonstrating that static stiffness can replicate Sun 2020's effect, the entire mechanism chain is ungrounded in the ECM context.

---

## META-CRITIQUE

### Kill Rate Analysis
- **Kill rate**: 2/7 = 29%
- **Assessment**: Within the healthy range (30-50% target, 29% is borderline acceptable). Two kills on solid mechanistic grounds.
- **C2-H4 kill**: Time-scale mismatch (PIEZO1 ms-inactivation vs. calcineurin minutes-requirement) is a QUALITATIVE mechanism failure, not a quantitative uncertainty.
- **C2-H5 kill**: <50% groundedness (33%), three unverified mechanism steps in series, force-based chromatin access echoing C1 kills, hallucination-as-novelty red flag.

### Verdict Distribution
| Hypothesis | Verdict | Confidence Change | Key Issue |
|------------|---------|-------------------|-----------|
| C2-H1 | SURVIVE_REVISED | 5→3 | Cofactors in quantitative excess of enzyme Km |
| C2-H2 | SURVIVE_REVISED | 5→4 | UTX-COMPASS can be independently recruited |
| C2-H3 | SURVIVE_REVISED | 4→3 | Differential threshold unverified; shared RhoA/ROCK upstream |
| C2-H4 | KILL | 4→1 | PIEZO1 inactivation kinetics vs calcineurin time-scale |
| C2-H5 | KILL | 3→1 | <50% groundedness; 3 unverified mechanism steps |
| C2-H6 | SURVIVE_REVISED | 5→4 | HDAC1/2 compensation; Fu 2024 context-specific |
| C2-H7 | SURVIVE_REVISED | 4→3 | Cyclic→static force transfer; KDM4A speculative |

### Cross-Hypothesis Pattern Analysis
1. **Force-based mechanisms remain problematic**: C2-H4 (PIEZO1 kinetics) and C2-H5 (nuclear deformation → EP300 access) both involve direct mechanical force effects on molecular processes. C2-H7 partially escapes because it leverages Sun 2020's experimental evidence, but the cyclic→static concern persists.
2. **Signaling-based mechanisms are stronger**: C2-H1 (metabolic cofactors), C2-H2 (enzymatic cascade), C2-H3 (pathway thresholds), and C2-H6 (eraser depletion) all operate through biochemical signaling cascades downstream of mechanotransduction, avoiding direct force → chromatin claims. These are more grounded.
3. **C2-H6 is the standout**: Genuinely orthogonal mechanism, best experimental design, creative conceptual inversion. Should be prioritized for ranking.

### Self-Audit
- All 7 hypotheses received all 9 attack vectors: ✓
- No WebSearch/WebFetch used (BLIND MODE): ✓
- Claim-level verification performed for every hypothesis: ✓
- Citation verification for every grounded claim: ✓
- One possible journal misattribution (Macian 2001) and one possible PMID error (Chaudhuri 2016) flagged: ✓
- Kill rate 29% — borderline but honest. Every SURVIVE_REVISED has a clear "strongest reason to kill" documented.

### For each SURVIVE: did I verify specific [GROUNDED] claims?
- C2-H1: Yes — all 6 grounded claims verified (Wellen, Enzo, Carey, Agger, Tahiliani, Bertero). ✓
- C2-H2: Yes — all 5 grounded claims verified (EP300-BRD4, CTGF/CYR61, Dorighi, TET2, TDG). ✓
- C2-H3: Yes — all 4 grounded claims verified (Miralles, Dupont, CArG, TEAD). ✓
- C2-H6: Yes — all 4 grounded claims verified (Fu, You, Xu, Watson). ✓
- C2-H7: Yes — all 3 grounded claims verified (Sun, Roadmap, H3K4me1+H3K9me3). ✓
